Premium
Simvastatin (40mg/day) Reduced the Activity of Circulating Plasminogen Activator Inhibitor 1 in Volunteers with Metabolic Syndrome
Author(s) -
Wang Long,
Rockwood Jason,
Zak Danielle,
Devaraj Sridevi,
Jialal Ishwarlal
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1123.21
Subject(s) - simvastatin , medicine , metabolic syndrome , plasminogen activator inhibitor 1 , endocrinology , placebo , plasminogen activator , atorvastatin , concomitant , diabetes mellitus , alternative medicine , pathology
The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that Simvastatin has concomitant benefits in reducing LDL‐cholesterol and inflammation in MS subjects. Plasminogen Activator Inhibitor 1(PAI‐1) levels are increased in MS. The current study was to investigate the effects of simvastatin on sP‐selectin, sCD40 ligand, and PAI‐1 which play important roles in the development of atherosclerosis. Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at 0 and 8 weeks. PAI‐1, sP‐selectin and sCD40 ligand values were obtained by ELISA. There was no baseline differences in any of the parameters studied. Compared to baseline, simvastatin significantly (P<0.05) reduced the circulating PAI‐1 activity (24.3 ± 5.2 U/mL at baseline vs. 21.4 ± 3.9 U/mL after 8 weeks of treatment). Simvistatin did not alter (P>0.05) the levels of sP‐selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40 (2.0 ± 1.6 μg/L at baseline vs. 1.5 ± 1.0 μg/L after 8 weeks). Our data indicate that simvastatin therapy has significant effects on the fibronolytic system in MS subjects as evidenced in a reduction in PAI‐1.